Rossari Biotech Limited
Bombay Stock ExchangeTotal Valuation
Rossari Biotech Limited carries a market capitalization of 29.41B, placing it among publicly traded companies globally. Its enterprise value stands at 38.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.41B |
| Enterprise Value | 38.15B |
Valuation Ratios
Rossari Biotech Limited trades at a trailing price-to-earnings ratio of 28.25.
| PE Ratio | 28.25 |
| PS Ratio | 1.79 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Rossari Biotech Limited trades at an EV/EBITDA multiple of 19.21 and an EV/FCF ratio of 262.19. The EV/Sales ratio of 1.79 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.21 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.79 |
| EV / EBITDA | 19.21 |
| EV / EBIT | 19.21 |
| EV / FCF | 262.19 |
Financial Position
Rossari Biotech Limited maintains a current ratio of 4.02, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.77, indicating elevated leverage, while an interest coverage ratio of 10.00 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 4.02 |
| Quick Ratio | 0.40 |
| Debt / Equity | 32.77 |
| Debt / EBITDA | N/A |
| Interest Coverage | 10.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 107.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Rossari Biotech Limited has paid 492.21M in income taxes, reflecting an effective tax rate of 26.71.
| Income Tax | 492.21M |
| Effective Tax Rate | 26.71 |
Stock Price Statistics
Rossari Biotech Limited's stock has declined approximately -22.47609% over the past 52 weeks. The 50-day moving average sits at 480.43, while the 200-day moving average is 558.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -22.47609% |
| 50-Day Moving Average | 480.43 |
| 200-Day Moving Average | 558.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Rossari Biotech Limited generated 21.34B in revenue and converted that into 1.35B in net income, yielding earnings per share of 24.37. EBITDA reached 1.99B, while operating income came in at 1.99B.
| Revenue | 21.34B |
| Gross Profit | 6.71B |
| Operating Income | 1.99B |
| Pretax Income | 1.84B |
| Net Income | 1.35B |
| EBITDA | 1.99B |
| EBIT | 1.99B |
| Earnings Per Share (EPS) | 24.37 |
Margins
Rossari Biotech Limited operates with a gross margin of 31.42, reflecting its pricing power and cost economics. The operating margin of 9.30 and net profit margin of 6.33 provide insight into operational efficiency.
| Gross Margin | 31.42 |
| Operating Margin | 9.30 |
| Pretax Margin | 8.63 |
| Profit Margin | 6.33 |
| EBITDA Margin | 9.30 |
Scores
Rossari Biotech Limited posts an Altman Z-Score of 12.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.66 |